Alterity Therapeutics Limited (ATHE): Price and Financial Metrics


Alterity Therapeutics Limited (ATHE): $3.91

0.10 (+2.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATHE Stock Price Chart Interactive Chart >

Price chart for ATHE

ATHE Price/Volume Stats

Current price $3.91 52-week high $10.50
Prev. close $3.81 52-week low $2.90
Day low $3.80 Volume 25,900
Day high $3.97 Avg. volume 23,439
50-day MA $3.59 Dividend yield N/A
200-day MA $5.33 Market Cap 15.68M

Alterity Therapeutics Limited (ATHE) Company Bio


Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.


ATHE Latest News Stream


Event/Time News Detail
Loading, please wait...

ATHE Latest Social Stream


Loading social stream, please wait...

View Full ATHE Social Stream

Latest ATHE News From Around the Web

Below are the latest news stories about ALTERITY THERAPEUTICS LTD that investors may wish to consider to help them evaluate ATHE as an investment opportunity.

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA)

Yahoo | January 25, 2023

Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?

Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.

Yahoo | January 20, 2023

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.

Yahoo | January 9, 2023

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the "ADS Ratio") from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the "ADS Ratio Change"). The ADS Ratio Change will

Yahoo | January 6, 2023

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.

Yahoo | January 3, 2023

Read More 'ATHE' Stories Here

ATHE Price Returns

1-mo 13.33%
3-mo -2.86%
6-mo -34.27%
1-year -53.40%
3-year -50.42%
5-year -85.88%
YTD 12.29%
2022 -51.64%
2021 -46.27%
2020 71.79%
2019 -39.06%
2018 -58.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9052 seconds.